Cargando…

P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS

Detalles Bibliográficos
Autores principales:	Aguirre, Luis E., Jain, Akriti, Ball, Somedeb, Al Ali, Najla, Sallman, David, Kuykendall, Andrew, Chan, Onyee, Xie, Zhuoer, Walker, Alison, Sweet, Kendra, Lancet, Jeffrey, Padron, Eric, S. Komrokji, Rami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428761/ http://dx.doi.org/10.1097/01.HS9.0000969812.65557.34

Ejemplares similares

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
por: Komrokji, Rami, et al.
Publicado: (2022)

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Jain, Akriti G, et al.
Publicado: (2021)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021)

Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report
por: Hu, Lianbo, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center
por: Wang, Chao, et al.
Publicado: (2022)

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
por: Robert Savona, Michael, et al.
Publicado: (2023)

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature
por: Elli, Elena, et al.
Publicado: (2012)

Efficient Induction of Extrinsic Cell Death by Dandelion Root Extract in Human Chronic Myelomonocytic Leukemia (CMML) Cells
por: Ovadje, Pamela, et al.
Publicado: (2012)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL)
por: Soriano, Paolo K., et al.
Publicado: (2018)

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
por: Komrokji, Rami, et al.
Publicado: (2022)

Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing
por: Rechsteiner, Markus, et al.
Publicado: (2014)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
por: Benites, Bruno Deltreggia, et al.
Publicado: (2013)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
por: Calvo, Xavier, et al.
Publicado: (2022)

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia
por: Talati, Chetasi, et al.
Publicado: (2020)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling
por: Bell, Gillian C., et al.
Publicado: (2015)

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
por: Padron, E, et al.
Publicado: (2015)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS
por: Gu, Siyu, et al.
Publicado: (2021)

Transformation of CMML to AML presenting with acute kidney injury
por: DeBoer, Rebecca, et al.
Publicado: (2020)

P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT
por: Zhang, Y., et al.
Publicado: (2022)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

727. Outcomes of Antibiotic Use in Ischemic Colitis
por: Poenaru, Sonia, et al.
Publicado: (2020)

Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia
por: Kitazawa, Hironobu, et al.
Publicado: (2021)

P536: A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS
por: Dinardo, Courtney, et al.
Publicado: (2023)

Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia
por: Yuan, Hongwei, et al.
Publicado: (2019)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

CDK8 as the STAT1 serine 727 kinase?
por: Staab, Julia, et al.
Publicado: (2013)

727 Development of an Acuity and Scheduling System for Wound Care
por: Salazar, Elizabeth, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q8c6j62d9dpi9j2e60lel7q19j